The study is a collaboration between several teams of researchers. The results extrapolated by Retrogenix enables researchers from the Unniversity of Copenhagen, Seattle Biomedical Research Institute, the University of Oxford and the National Institute for Medical Research (Tanzania) to show that the malaria parasite binds a protein in blood vessel walls which is involved with regulating blood coagulation and the inflammatory process. This is a vital step in the drug therapy and vaccine research process because malaria parasites kill their host by sticking to the sides of blood vessels.
Dr. Matthew Higgins from the University of Oxford explains: “Now that we know the pair of proteins involved, we can begin zooming further in to reveal the molecular details of how malaria parasites grab onto the sides of blood vessels. We want to know exactly which bits of the parasite protein are needed to bind to the receptor in the blood vessel wall. Then, we can aim to design vaccines or drugs to prevent this binding.”
The results of the study have been published in Nature. Further details about the specific work that Retrogenix contributed to the study using their Cell Microarray Technology is also detailed on the Retrogenix website.